Cancer Molecular Basis

Cancer is not a single disease but a collection of disorders that share a common hallmark: uncontrolled cell proliferation. At its core, cancer arises from genetic and epigenetic changes that disrupt normal regulatory networks, allowing cells to ignore growthinhibitory signals, evade death, and acquire new capabilities such as metastasis. Understanding these molecular alterations is essential for diagnosis, treatment, and prevention.

1. The Hallmarks of Cancer

Hanahan and Weinberg summarized the essential capabilities that a transformed cell must acquire:

• Sustaining proliferative signaling Mutations in growthfactor receptors (e.g., EGFR, HER2) or downstream pathways (RASRAFMEKERK, PI3KAKT) keep mitogenic signals permanently on.
• Evading growth suppressors Inactivation of tumorsuppressor genes such as TP53 or RB1 removes brakes on the cell cycle.
• Resisting cell death Overexpression of antiapoptotic proteins (BCL2, IAPs) or loss of proapoptotic factors blocks programmed cell death.
• Enabling replicative immortality Reactivation of telomerase (TERT) or alternative lengthening of telomeres (ALT) preserves chromosome ends.
• Inducing angiogenesis Production of VEGF and other proangiogenic factors creates a blood supply for tumors.
• Activating invasion and metastasis Epithelialtomesenchymal transition (EMT) and matrixdegrading enzymes (MMPs) facilitate spread.
• Genome instability & mutation Defects in DNArepair mechanisms (MMR, homologous recombination) raise mutation rates.
• Tumorpromoting inflammation Cytokines and immune cells create a microenvironment that supports growth.
• Reprogramming energy metabolism The Warburg effect shifts cells to glycolysis even in oxygenrich conditions.

2. Key Genetic Alterations

2.1 Oncogenes

Oncogenes are mutated or amplified versions of normal (proto)genes that drive proliferation. Classic examples include:

• RAS family (KRAS, NRAS, HRAS) Point mutations lock the GTPase in an active state, continuously stimulating MAPK signaling.
• MYC Amplification leads to global transcriptional amplification and metabolic reprogramming.
• ERBB2/HER2 Gene amplification in breast and gastric cancers triggers potent tyrosinekinase signaling.
• BCRABL A fusion protein from the Philadelphia chromosome (t(9;22)) has constitutive kinase activity, driving chronic myeloid leukemia.

2.2 TumorSuppressor Genes

These genes normally restrain growth; loss of function predisposes cells to malignancy.

• TP53 The guardian of the genome. Mutations prevent DNA damageinduced cellcycle arrest and apoptosis.
• RB1 Controls the G1/S checkpoint; its inactivation frees E2F transcription factors.
• BRCA1/2 Central to homologous recombination repair; germline mutations dramatically increase breast and ovarian cancer risk.
• PTEN Negative regulator of PI3KAKT signaling; loss results in unchecked survival signals.

2.3 DNARepair Defects

Deficiencies in mismatch repair (MMR) cause microsatellite instability (MSI), while defective nucleotideexcision repair (NER) leads to xeroderma pigmentosum. Such genomic instability fuels mutation accumulation.

3. Epigenetic Contributions

Beyond DNA sequence changes, cancer cells remodel their epigenome:

• DNA methylation Hypermethylation of promoter CpG islands silences tumorsuppressor genes (e.g., CDKN2A).
• Histone modifications Aberrant acetylation or methylation patterns alter chromatin accessibility, influencing gene expression.
• Noncoding RNAs microRNAs (miR21, miR155) can act as oncogenes or tumor suppressors by posttranscriptionally regulating target mRNAs.

4. Signaling Pathways Frequently Dysregulated

4.1 MAPK/ERK Pathway

Triggered by RTKs, it proceeds RAS RAF MEK ERK. Mutations in RAS or BRAF (e.g., V600E) cause constitutive signaling, promoting proliferation and survival.

4.2 PI3K/AKT/mTOR Pathway

Activation (by growth factors or PTEN loss) drives growth, protein synthesis, and inhibits apoptosis. mTOR inhibitors (e.g., rapamycin) are clinically used in some tumors.

4.3 Wnt/catenin Pathway

Stabilization of catenin (via APC loss or CTNNB1 mutation) leads to transcription of proliferative genes. Frequently altered in colorectal cancer.

4.4 Hedgehog Pathway

Aberrant activation (e.g., SMO mutations) drives basal cell carcinoma and medulloblastoma; inhibitors like vismodegib are approved therapies.

5. Metastasis Molecular Steps

Metastasis involves a cascade of events, each with distinct molecular drivers:

1. Local invasion Upregulation of matrix metalloproteinases (MMP2, MMP9) degrades basement membranes.
2. Intravasation Interaction with tumorassociated macrophages (TAMs) and EMT transcription factors (SNAIL, TWIST) facilitate entry into circulation.
3. Survival in bloodstream Platelet cloaking and expression of antiapoptotic proteins protect circulating tumor cells.
4. Extravasation & colonization Chemokine receptors (CXCR4) guide cells to distant niches; supportive stromal signaling (TGF) enables outgrowth.

6. Clinical Implications of Molecular Knowledge

6.1 Targeted Therapies

Drugs are designed to inhibit specific altered proteins:

• EGFR inhibitors (erlotinib, gefitinib) in EGFRmutant lung cancer.
• BRAF inhibitors (vemurafenib, dabrafenib) for BRAFV600E melanoma.
• PARP inhibitors (olaparib) exploit synthetic lethality in BRCAdeficient tumors.
• CDK4/6 inhibitors (palbociclib) restore control of the G1/S checkpoint in RBintact breast cancer.

6.2 Immunotherapy

Mutational burden creates neoantigens recognized by the immune system. Checkpoint inhibitors (antiPD1, antiCTLA4) release the brakes on Tcells, producing durable responses in tumors with high MSI or PDL1 expression.

6.3 BiomarkerDriven Diagnosis

Liquid biopsies detect circulating tumor DNA (ctDNA) bearing characteristic mutations, enabling early detection, monitoring of treatment response, and identification of resistance mechanisms.

7. Future Directions

Continued integration of genomics, transcriptomics, proteomics, and singlecell technologies will refine our understanding of tumor heterogeneity. Emerging concepts include:

• Neoantigen vaccines tailored to a patients mutational landscape.
• CRISPRbased gene editing to correct driver mutations in situ.
• Metabolomics targeting cancerspecific metabolic dependencies.
• Spatial transcriptomics mapping tumormicroenvironment interactions at singlecell resolution.

By dissecting the molecular circuitry that underlies malignancy, researchers and clinicians are moving toward ever more precise, less toxic, and more effective strategies to prevent, detect, and treat cancer.

References: Hanahan & Weinberg, Cell 2011; Vogelstein et al., Nat Rev Cancer 2013; National Cancer Institute (cancer.gov).